Drug Trial Radar · NCT05322616
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 21, 2022
Primary completion
May 26, 2023
Study completion May 26, 2023
Sponsor
- Lead sponsor
- Salubris Biotherapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
JK07Drug
Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Matching PlaceboDrug
Vehicle control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety AssessmentTime frame: Screening to Day 28
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Stanford University Medical Center
Stanford, California
Harvard Medical School/Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Oregon Health and Science University Hospital
Portland, Oregon
Houston Methodist Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.